Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats
| العنوان: | Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats |
|---|---|
| المؤلفون: | Daisuke Ichikawa, Keiichi Ohata, Yasunori Natsuki, Yoshio Nagai, Atsuko Kamijo-Ikemori, Shiika Watanabe, Kazuho Inoue, Takeshi Sugaya, Yuji Ogura, Jun Tanabe, Yugo Shibagaki, Seiko Hoshino, Kenjiro Kimura, Shohei Yamada |
| المصدر: | Clinical and Experimental Nephrology. 25:365-375 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Blood Glucose, Male, medicine.medical_specialty, Physiology, medicine.medical_treatment, 030232 urology & nephrology, Blood Pressure, Type 2 diabetes, 030204 cardiovascular system & hematology, Kidney, Incretins, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Physiology (medical), Diabetes mellitus, Internal medicine, Hyperlipidemia, Autophagy, medicine, Albuminuria, Animals, Hypoglycemic Agents, Diabetic Nephropathies, Liraglutide, business.industry, Insulin, Glomerulosclerosis, Rats, Inbred Strains, Hydralazine, medicine.disease, Disease Models, Animal, Endocrinology, Blood pressure, Diabetes Mellitus, Type 2, Nephrology, business, Biomarkers, Signal Transduction, medicine.drug |
| الوصف: | The aim of this study is to investigate the renoprotective effect of the GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease (DKD) using an animal model of type 2 diabetes with several metabolic disorders. Male 8-week-old spontaneously diabetic Torii (SDT) fatty rats (n = 19) were randomly assigned to three groups. The liraglutide group (n = 6) was injected subcutaneously with liraglutide. Another treatment group (n = 6) received subcutaneous insulin against hyperglycemia and hydralazine against hypertension for matching blood glucose levels and blood pressure with the liraglutide group. The control groups of SDT fatty (n = 7) and non-diabetic Sprague–Dawley rats (n = 7) were injected only with a vehicle. The control group of SDT fatty rats exhibited hyperglycemia, obesity, hypertension, hyperlipidemia, glomerular sclerosis, and tubulointerstitial injury with high urinary albumin and L-FABP levels. Liraglutide treatment reduced body weight, food intake, blood glucose and blood pressure levels, as well as ameliorated renal pathologic findings with lower urinary albumin and L-FABP levels. Liraglutide increased expressions of phosphorylated (p)-eNOS and p-AMPK in glomeruli, downregulated renal expression of p-mTOR, and increased renal expressions of LC3B-II, suggesting activation of autophagy. However, these effects were not caused by the treatments with insulin and hydralazine, despite comparable levels of hyperglycemia and hypertension to those achieved with liraglutide treatment. Liraglutide may exert a renoprotective effect via prevention of glomerular endothelial abnormality and preservation of autophagy in early-phase DKD, independent of blood glucose, and blood pressure levels. |
| تدمد: | 1437-7799 1342-1751 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d4ff52c66a87492d577ea553a82e7d7Test https://doi.org/10.1007/s10157-020-02007-2Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....2d4ff52c66a87492d577ea553a82e7d7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14377799 13421751 |
|---|